Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms

The treatment for anaplastic lymphoma kinase (ALK)‐positive lung cancer has been rapidly evolving since the introduction of several ALK tyrosine kinase inhibitors (ALK‐TKI) in clinical practice. However, the acquired resistance to these drugs has become an important issue. In this study, we collecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanagitani, Noriko, Uchibori, Ken, Koike, Sumie, Tsukahara, Mika, Kitazono, Satoru, Yoshizawa, Takahiro, Horiike, Atsushi, Ohyanagi, Fumiyoshi, Tambo, Yuichi, Nishikawa, Shingo, Fujita, Naoya, Katayama, Ryohei, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060465/
https://www.ncbi.nlm.nih.gov/pubmed/31961053
http://dx.doi.org/10.1111/cas.14314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060465/
https://www.ncbi.nlm.nih.gov/pubmed/31961053
http://dx.doi.org/10.1111/cas.14314

Ejemplares similares